8-KOther Events

PFIZER INC 8-K Report, Corporate Update (Nov 13, 2025)

Filed November 13, 2025For Securities:PFE

Summary

Pfizer Inc. announced the successful completion of its acquisition of Metsera, Inc. for an enterprise value of approximately $7.0 billion. This strategic move signifies Pfizer's expansion into the obesity and metabolic disease market, a key growth area. The acquisition was executed through a merger agreement, with Metsera shareholders receiving $65.60 in cash per share at closing. In addition to the upfront cash payment, Metsera shareholders are eligible to receive contingent value rights (CVRs) worth up to an additional $20.65 per share. These CVRs are tied to the achievement of specific developmental and regulatory milestones related to Metsera's pipeline, notably its GLP-1 receptor antagonist and amylin analog drug candidates. Investors should closely monitor the progress of MET-097i and MET-233i, as their successful advancement could represent significant future value creation for Pfizer.

Key Highlights

  • 1Pfizer Inc. has completed the acquisition of Metsera, Inc.
  • 2The enterprise value of the acquisition is approximately $7.0 billion.
  • 3Metsera shareholders received $65.60 in cash per share at closing.
  • 4Contingent Value Rights (CVRs) of up to $20.65 per share are available to Metsera shareholders.
  • 5CVRs are tied to three specific milestones related to Metsera's pipeline candidates, MET-097i and MET-233i.
  • 6Milestones include initiation of Phase 3 trials and FDA approvals for both monotherapy and combination treatments.

Frequently Asked Questions

The acquisition of Metsera is a strategic move by Pfizer to expand its presence and pipeline in the growing market for obesity and metabolic diseases, leveraging Metsera's innovative drug candidates.

Metsera shareholders received $65.60 in cash per share at closing, and are eligible for up to an additional $20.65 per share through contingent value rights, bringing the total potential value per share to $86.25 if all milestones are achieved.

The CVRs are tied to three specific milestones: (i) initiation of the Phase 3 clinical trial for the combination therapy, (ii) FDA approval of Metsera's monthly MET-097i monotherapy, and (iii) FDA approval of the monthly MET-097i+MET-233i combination therapy.

The contingent value rights are primarily linked to Metsera's injectable GLP-1 receptor antagonist MET-097i and amylin analog MET-233i, both in their monotherapy and combination forms.